Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014
For the nine months, the company's contract revenue was $7,214,000 against $3,045,000 a year ago. Income from operations was $445,000 against loss of $2,031,000 a year ago. Net income was $445,000 or $0.00 per basic and diluted share against net loss of $2,541,000 or $0.03 per basic and diluted share a year ago. Net cash provided by operating activities was $403,000 against net cash used in operating activities of $1,107,000 a year ago.